From curated matchmaking to clinic bedsides: Sooma and Clariane’s cross border pilot

In 2025 the European Innovation Council’s Corporate Partnership Programme organised a structured engagement between Clariane, one of Europe’s largest care and healthcare groups, and 14 EIC-backed start-ups. The process moved beyond short demonstrations to an operational partnership with Sooma, a Finnish MedTech company supported by the EIC Accelerator, producing what the EIC describes as a concrete cross-border deployment. Sooma’s non-invasive brain stimulation headset is now being rolled out across more than 35 Clariane clinics and nursing homes in five European countries and an 18 month pilot launched in 2026 will evaluate feasibility and acceptability as part of an effort to scale evidence based alternatives for mental health and neurorehabilitation care.

Who the partners are and why this matters

The deal brings together three elements common in the current European deep tech policy playbook: a large corporate or care group with clear operational needs, EIC-backed start-ups offering disruptive clinical technologies, and structured business acceleration and matchmaking provided by EIC Business Acceleration Services. For Clariane the collaboration is framed as part of a larger digital and clinical transformation spanning 1,215 facilities and supporting roughly 840,000 residents and patients across six countries. For Sooma it represents a pathway to clinical deployments at scale across a multi-country care network.

How the collaboration progressed

The selection and contracting process followed a staged path described in the EIC reporting. In mid 2025 Clariane published an open call for solutions in diagnostics, digital patient pathways and mental health or neurological rehabilitation. From 56 initial responses, 14 EIC-backed firms were invited to a Corporate Day in Paris in June 2025. Sooma emerged as a strong match because its device reportedly met Clariane’s clinical specifications and had a high technology readiness level.

What followed was sequential engagement and validation: Sooma participated in Clariane Innovation Days on neuromodulation in Milan in September 2025 and in a mental health event in Barcelona in December 2025. The parties signed a Letter of Intent in December 2025 and finalised a framework contract in June 2026. According to public accounts, deployment of Sooma’s headset now covers more than 35 Clariane clinics and nursing homes in five European countries and an 18 month pilot launched in 2026 will test integration across care pathways.

What the technology is and the evidence questions

Sooma’s headset is described in public materials and in EIC communications as CE marked and positioned at technology readiness level TRL 8–9. That indicates regulatory conformity to essential safety and performance requirements for medical devices in the EU and that the device has been used in real world settings. Nevertheless, the move from device approval to routine clinical use across multiple countries requires additional work on clinical protocols, staff training, patient selection, data capture and long term outcome measurement.

Voices from the process

EIC and partner statements emphasise matchmaking and practical validation. Clariane’s Chief Digital & Information Officer framed the EIC role as bridging corporate needs and mature European innovation. Clinical leads at Clariane pointed to Sooma’s fit with operational specifications, its CE marking and high TRL as reasons for selection. Sooma’s cofounder framed the collaboration as a route to broader access for evidence based neuromodulation therapies across Europe.

Risks, open questions and practical challenges

The public account of the partnership contains important, verifiable milestones. At the same time readers should note that a deployment reported as 'across more than 35 facilities in 5 countries' is an operational claim from the parties and the EIC communication. The core evaluation of clinical effectiveness and long term value remains the purpose of the 18 month pilot. Key issues to watch during the pilot and before wider scaling include:

How the EIC model contributed and what to expect next

The EIC Corporate Partnership Programme is designed to do the early stage work that large corporates and public buyers often cannot run at scale by themselves. The programme curates corporate problem statements, prepares startups for pitches, provides coaching and creates a pathway to pilots. The Sooma-Clariane case shows the model working end to end from scouting to contract. It also illustrates the predictable next phase: operational pilots followed by careful evaluation before a commercial roll out.

If the 18 month pilot demonstrates clinical benefit, good safety, and an economically sustainable model, the parties may seek broader rollouts and reimbursement discussions. Absent robust outcome data, deployments risk remaining local proofs of concept without systemic change. For policymakers, the case is a reminder that public funding and curated matchmaking can accelerate trials and real life testing. For clinicians and patients, it is a reminder to scrutinise evidence beyond device claims before changing standard practice.

Bottom line

The EIC enabled matchmaking that turned an innovation pitch into a multi country pilot and a framework contract between a regulated care group and an EIC-backed MedTech start-up. That progression is exactly what the EIC programmes aim to achieve. The important test now is the pilot itself. Its results will determine whether the reported deployment translates into durable, evidence based change in mental health and neurorehabilitation care across the participating countries.